Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMN AMN Healthcare Services	$21.94 -1.9%	$20.73	$17.45 ▼ $70.07	$839.71M	0.19	896,804 shs	944,011 shs
CRSP CRISPR Therapeutics	$44.25 -0.4%	$38.61	$30.04 ▼ $63.68	$3.82B	1.75	1.78 million shs	3.05 million shs
DNLI Denali Therapeutics	$13.89 -1.4%	$14.32	$10.57 ▼ $33.33	$2.02B	1.33	1.12 million shs	1.53 million shs
FOLD Amicus Therapeutics	$5.64 -1.6%	$6.39	$5.62 ▼ $12.65	$1.74B	0.54	3.08 million shs	17.42 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMN AMN Healthcare Services	0.00%	+1.79%	+5.56%	-10.72%	-58.60%
CRSP CRISPR Therapeutics	0.00%	+6.99%	+20.05%	+3.82%	-21.32%
DNLI Denali Therapeutics	0.00%	-4.54%	+3.50%	-5.89%	-38.62%
FOLD Amicus Therapeutics	0.00%	-6.47%	-9.32%	-35.10%	-44.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMN AMN Healthcare Services	4.3122 of 5 stars	3.1	2.0	4.3	3.0	1.7	1.9
CRSP CRISPR Therapeutics	3.1234 of 5 stars	4.2	2.0	0.0	2.1	2.5	0.6
DNLI Denali Therapeutics	4.3665 of 5 stars	4.5	1.0	4.7	2.7	2.5	0.0
FOLD Amicus Therapeutics	3.9636 of 5 stars	3.4	2.0	4.3	1.8	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMN AMN Healthcare Services	2.25	Hold	$32.08	46.26% Upside
CRSP CRISPR Therapeutics	2.47	Hold	$69.53	57.14% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.71	142.72% Upside
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	187.63% Upside

Current Analyst Ratings Breakdown

Latest AMN, FOLD, DNLI, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00 ➝ $86.00
5/20/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00 ➝ $81.00
5/20/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/13/2025	AMN AMN Healthcare Services	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.50
5/9/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/8/2025	CRSP CRISPR Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$53.00 ➝ $47.00
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $81.00
5/7/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $82.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMN AMN Healthcare Services	$2.98B	0.28	$13.71 per share	1.60	$18.56 per share	1.18
CRSP CRISPR Therapeutics	$37.31M	102.42	N/A	N/A	$22.64 per share	1.95
DNLI Denali Therapeutics	$330.53M	6.11	N/A	N/A	$8.53 per share	1.63
FOLD Amicus Therapeutics	$528.29M	3.29	N/A	N/A	$0.65 per share	8.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMN AMN Healthcare Services	-$146.98M	-$4.33	N/A	9.06	N/A	-5.80%	13.39%	4.17%	8/6/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	13.12	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)

Latest AMN, FOLD, DNLI, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	AMN AMN Healthcare Services	$0.19	$0.45	+$0.26	-$0.03	$670.08 million	$689.53 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMN AMN Healthcare Services	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMN AMN Healthcare Services	1.39	1.08	1.08
CRSP CRISPR Therapeutics	N/A	15.64	15.64
DNLI Denali Therapeutics	N/A	9.56	9.56
FOLD Amicus Therapeutics	2.02	3.34	2.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMN AMN Healthcare Services	99.23%
CRSP CRISPR Therapeutics	69.20%
DNLI Denali Therapeutics	92.92%
FOLD Amicus Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AMN AMN Healthcare Services	0.93%
CRSP CRISPR Therapeutics	4.10%
DNLI Denali Therapeutics	12.50%
FOLD Amicus Therapeutics	2.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMN AMN Healthcare Services	2,968	38.28 million	37.93 million	Optionable
CRSP CRISPR Therapeutics	473	86.36 million	82.82 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable

AMN, FOLD, DNLI, and CRSP Headlines

Recent News About These Companies

U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts

June 20 at 5:03 PM | globenewswire.com

SG Americas Securities LLC Acquires 58,496 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

June 20 at 3:27 AM | marketbeat.com

Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week Low - Time to Sell?

June 17, 2025 | marketbeat.com

Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.22

June 17, 2025 | americanbankingnews.com

The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy

June 16, 2025 | globenewswire.com

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Analysts

June 14, 2025 | marketbeat.com

In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid

June 13, 2025 | globenewswire.com

In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime

June 12, 2025 | globenewswire.com

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma

June 12, 2025 | seekingalpha.com

Wedge Capital Management L L P NC Decreases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

June 11, 2025 | marketbeat.com

Zacks Research Analysts Decrease Earnings Estimates for FOLD

June 6, 2025 | marketbeat.com

New Strong Sell Stocks for June 3rd

June 3, 2025 | zacks.com

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

June 3, 2025 | globenewswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 471,902 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

June 1, 2025 | marketbeat.com

Two Sigma Advisers LP Buys 52,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

June 1, 2025 | marketbeat.com

Two Sigma Investments LP Boosts Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

June 1, 2025 | marketbeat.com

Millennium Management LLC Has $4.31 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

May 31, 2025 | marketbeat.com

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

May 30, 2025 | globenewswire.com

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Decreased by Voloridge Investment Management LLC

May 27, 2025 | marketbeat.com

Woodline Partners LP Sells 726,952 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

May 27, 2025 | marketbeat.com

Man Group plc Cuts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

May 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMN, FOLD, DNLI, and CRSP Company Descriptions

AMN Healthcare Services NYSE:AMN

$21.94 -0.41 (-1.85%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$21.92 -0.02 (-0.10%)

As of 06/20/2025 04:20 PM Eastern

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

CRISPR Therapeutics NASDAQ:CRSP

$44.25 -0.18 (-0.41%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$44.26 +0.02 (+0.03%)

As of 06/20/2025 07:52 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Denali Therapeutics NASDAQ:DNLI

$13.89 -0.20 (-1.42%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$13.99 +0.10 (+0.69%)

As of 06/20/2025 05:08 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Amicus Therapeutics NASDAQ:FOLD

$5.64 -0.09 (-1.57%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$5.64 +0.00 (+0.09%)

As of 06/20/2025 07:33 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time